Champions Oncology IncNASDAQ:CSBR
- LAST PRICE4.4000
- TODAY'S CHANGE (%)-0.1500 (-3.2967%)
- Bid / Lots4.2600/ 1
- Ask / Lots4.5100/ 1
- Open / Previous Close4.2600 / 4.5500
- Day Range
- 52 Week Range
- Volume4,199
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CSBR |
|---|---|---|
| 09:32 ET | 741 | 4.25 |
| 09:46 ET | 120 | 4.26 |
| 09:53 ET | 100 | 4.26 |
| 10:33 ET | 1800 | 4.306 |
| 10:38 ET | 460 | 4.4 |
| 10:44 ET | 386 | 4.4 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Champions Oncology Inc | 61.9M | -17.3x | --- |
Precision BioSciences Inc | 55.7M | 9.7x | --- |
Metagenomi Inc | 70.8M | -0.8x | --- |
Repare Therapeutics Inc | 119.5M | -1.5x | --- |
RVL Pharmaceuticals PLC | 11.1K | 0.0x | --- |
Bioqual Inc | 60.4M | 126.2x | -25.28% |
Company Information
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Contact Information
- Headquarters
- One University Plaza,, Suite 307HACKENSACK, NJ, United States 07601
- Phone
- 201-808-8400
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Joel Ackerman
- Chief Executive Officer, Director
- Ronnie Morris
- Chief Financial Officer
- David Miller
- Lead Independent Director
- David Sidransky
- Independent Director
- Robert Brainin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $61.9M |
|---|---|
Revenue (TTM) | $51.7M |
Shares Outstanding | 13.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-0.25 |
Book Value | $-0.14 |
P/E Ratio | -17.3x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
